Author

J. J. Linderman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Bioengineering· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:mouse· 2 Organism:non-human primate· 2 Approach:statistical model· 2

Frequent Co-Authors

D. E. Kirschner· 3 shared J. L. Flynn· 3 shared H. J. Borish· 2 shared L. R. Joslyn· 2 shared A. A. Desai· 1 shared A. G. White· 1 shared A. Kopp· 1 shared C. A. Scanga· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

D. E. Kirschner

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

In vivo Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity Antibodies

A. Kopp, S. Dong, H. Kwon, T. Wang, A. A. Desai, J. J. Linderman, P. M. Tessier, G. M. Thurber

This study develops HALA antibodies that adjust ADC delivery based on tumor HER2 expression, improving efficacy across varying expression levels in preclinical models.

bioRxiv · Apr 6, 2024 · PreprintBioengineering

Optimizing tuberculosis treatment efficacy: comparing the standard regimen with Moxifloxacin-containing regimens

M. Budak, J. M. Cicchese, P. Maiello, H. J. Borish, A. G. White, H. B. Chishti, J. Tomko, L. J. Frye, D. Fillmore, K. Kracinovsky, J. Sakal, C. A. Scanga, P. L. Lin, V. Dartois, J. J. Linderman, , D. E. Kirschner

This study compares standard TB treatment with moxifloxacin-containing regimens using computational models and experimental validation to identify more effective and patient-friendly treatment options.

bioRxiv · Dec 18, 2022Pharmacology & Toxicology

Concomitant immunity to M. tuberculosis infection

L. R. Joslyn, J. L. Flynn, D. E. Kirschner, J. J. Linderman

This study uses a virtual host model to predict that concomitant immunity against M. tuberculosis is linked to tissue-resident memory T cells, with an estimated lifespan of 2-3 years in human lung tissue.

bioRxiv · Aug 2, 2022Immunology

A computational model tracks whole-lung Mycobacterium tuberculosis infection and predicts factors that inhibit dissemination

T. Wessler, L. R. Joslyn, H. J. Borish, H. P. Gideon, J. L. Flynn, D. E. Kirschner, J. J. Linderman

This paper develops a computational model to simulate Mtb infection in lungs and identifies factors that prevent bacterial dissemination.

bioRxiv · Jul 24, 2019Immunology